EXPO

Exponent is a genuinely high-quality business: a 55-year-old science-and-engineering consulting franchise that earns a 27.2% ROE on an asset-light balance sheet, a 20.6% operating margin, and converts profit to cash ($132M operating cash flow on $106M net income) with essentially no financial leverage (liabilities/equity 0.99x, but that's operating/deferred-comp, not debt, against $222M cash and $390M equity). The MD&A confirms the engine — FY2025 (the FY2026-labeled period) growth was led by dispute-related work and energy-sector demand (hydro, wildfire losses, battery storage, EV failure analysis), the kind of essential, recurring, expert-witness work that holds up through cycles. Management is returning capital aggressively: $97.1M of buybacks (up ~1600% YoY) plus $60.4M of dividends shrank the share count 3.1%.

The problem is that the growth has gone flat while the multiple has not. Revenue rose just 4.2%, and the bottom line actually went backwards — net income -2.7%, diluted EPS -1.9%, operating income +0.2%. Step back across the cycle and the stagnation is structural, not a blip: net income was $101M in FY2021 and $106M in FY2026, essentially zero five-year earnings growth, while operating margin slipped from 21.4% to 20.6% as compensation, reimbursable and G&A expenses all grew faster than revenue. This is a consultancy whose output is billable hours; with no backlog (its own risk factor) and headcount/utilization as the only levers, there is little operating leverage to reaccelerate earnings quickly.